BIOFORCE NANOSCIENCES HOLDINGS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $17.8K |
| Cost of Revenue | — | — | — | — | — | — | — | $13.4K |
| Gross Profit | — | — | — | — | — | — | — | $4.4K |
| Gross Margin | — | — | — | — | — | — | — | 24.5% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $67.0K | $67.4K | $49.0K | $62.5K | $79.0K | $81.0K | $50.9K |
| Operating Income | — | $-490.0K | $-490.4K | — | — | — | — | $-46.5K |
| Operating Margin | — | — | — | — | — | — | — | -261.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-490.0K | $-490.4K | — | — | — | — | $-46.5K |
| Income Tax Expense | — | — | — | — | — | — | — | $0 |
| Net Income | — | $-1.3M | $-490.4K | $-472.0K | $-485.5K | $-502.0K | $-158.4M | $-46.5K |
| Net Margin | — | — | — | — | — | — | — | -261.8% |
| EPS (Basic) | — | $-0.04 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-9.72 | $0.00 |
| EPS (Diluted) | — | $-0.04 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-9.72 | $0.00 |
| Shares Outstanding (Basic) | 33.5M | 33.2M | 29.3M | 29.3M | 29.3M | 29.3M | 29.3M | 15.3M |
| Shares Outstanding (Diluted) | 33.5M | 33.2M | 29.3M | 29.3M | 29.3M | 29.3M | 29.3M | 15.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |
People calculate too much and think too little.